Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein
- PMID: 16796706
- PMCID: PMC1885140
- DOI: 10.1111/j.1365-2125.2006.02689.x
Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein
Abstract
Aims: We determined whether or not the extent of drug interaction of fexofenadine by itraconazole is time-dependent.
Methods: In a randomized two-phase crossover study, itraconazole was administered orally for 6 days, and, on days 1, 3 and 6, fexofenadine was administered simultaneously. On another occasion, fexofenadine was administered alone.
Results: Itraconazole increased fexofenadine AUC(0, infinity), and the % change for difference was 178% (95% CI 1235, 3379), 205% (95% CI 1539, 3319) and 169% (95% CI 1128, 2987) on days 1, 3 and 6 of the 6 day treatment, respectively.
Conclusions: The extent of drug interaction by itraconazole was not time-dependent.
Similar articles
-
Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.Clin Pharmacol Ther. 2005 Aug;78(2):191-201. doi: 10.1016/j.clpt.2005.04.012. Clin Pharmacol Ther. 2005. PMID: 16084853 Clinical Trial.
-
Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine.Drug Metab Dispos. 2006 Nov;34(11):1875-9. doi: 10.1124/dmd.106.011023. Epub 2006 Aug 23. Drug Metab Dispos. 2006. PMID: 16928786 Clinical Trial.
-
Pharmacokinetics of fexofenadine enantiomers in healthy subjects.Chirality. 2007 Mar;19(3):223-7. doi: 10.1002/chir.20370. Chirality. 2007. PMID: 17230498
-
Clinical pharmacokinetics of fexofenadine enantiomers.Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):69-74. doi: 10.1517/17425250903382615. Expert Opin Drug Metab Toxicol. 2010. PMID: 19947891 Review.
-
Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans.Drugs R D. 2007;8(5):301-14. doi: 10.2165/00126839-200708050-00004. Drugs R D. 2007. PMID: 17767395 Review.
Cited by
-
Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.Clin Pharmacokinet. 2010 Apr;49(4):223-37. doi: 10.2165/11318000-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20214407 Review.
-
Evaluation of P-Glycoprotein Inhibitory Potential Using a Rhodamine 123 Accumulation Assay.Pharmaceutics. 2016 Apr 12;8(2):12. doi: 10.3390/pharmaceutics8020012. Pharmaceutics. 2016. PMID: 27077878 Free PMC article.
-
Fruit juice inhibition of uptake transport: a new type of food-drug interaction.Br J Clin Pharmacol. 2010 Nov;70(5):645-55. doi: 10.1111/j.1365-2125.2010.03722.x. Br J Clin Pharmacol. 2010. PMID: 21039758 Free PMC article. Review.
-
A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4.Clin Pharmacokinet. 2019 Apr;58(4):503-523. doi: 10.1007/s40262-018-0711-0. Clin Pharmacokinet. 2019. PMID: 30194612
-
Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.Br J Pharmacol. 2014 Feb;171(4):1043-53. doi: 10.1111/bph.12533. Br J Pharmacol. 2014. PMID: 24283665 Free PMC article.
References
-
- Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet. 2000;38:111–80. - PubMed
-
- Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38:41–57. - PubMed
-
- Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol. 1998;38:389–430. - PubMed
-
- Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg. 1996;82:511–6. - PubMed
-
- Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. Ther Drug Monit. 1997;19:609–13. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources